A Study of LY2784544 in Participants With Myeloproliferative Neoplasms

NCT01594723 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

110

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms, Hematologic

Interventions

DRUG: 120 mg LY2784544

Sponsor

Eli Lilly and Company